Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $93.08 in the prior trading day, Incyte Corp (NASDAQ: INCY) closed at $91.65, down -1.54%. In other words, the price has decreased by -$1.54 from its previous closing price. On the day, 6.88 million shares were traded. INCY stock price reached its highest trading level at $93.97 during the session, while it also had its lowest trading level at $84.02.
Ratios:
Our goal is to gain a better understanding of INCY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.68. For the most recent quarter (mrq), Quick Ratio is recorded 2.90 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 06, 2025, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $89.
On August 01, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $90.Barclays initiated its Overweight rating on August 01, 2025, with a $90 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 27 ’25 when BARRY FLANNELLY bought 33,452 shares for $91.73 per share.
Denton Sheila A. sold 277 shares of INCY for $23,581 on Oct 15 ’25. The EVP & General Counsel now owns 26,569 shares after completing the transaction at $85.13 per share. On Oct 16 ’25, another insider, BARRY FLANNELLY, who serves as the Officer of the company, bought 18,495 shares for $92.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 17897058304 and an Enterprise Value of 15038707712. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.36, and their Forward P/E ratio for the next fiscal year is 12.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.72 while its Price-to-Book (P/B) ratio in mrq is 4.27. Its current Enterprise Value per Revenue stands at 3.125 whereas that against EBITDA is 11.38.
Stock Price History:
The Beta on a monthly basis for INCY is 0.74, which has changed by 0.2590288 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $93.17, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 6.63%, while the 200-Day Moving Average is calculated to be 26.49%.
Shares Statistics:
The stock has traded on average 1.93M shares per day over the past 3-months and 2207560 shares per day over the last 10 days, according to various share statistics. A total of 195.28M shares are outstanding, with a floating share count of 192.91M. Insiders hold about 1.21% of the company’s shares, while institutions hold 103.30% stake in the company. Shares short for INCY as of 1760486400 were 9364129 with a Short Ratio of 4.85, compared to 1757894400 on 8697013. Therefore, it implies a Short% of Shares Outstanding of 9364129 and a Short% of Float of 6.77.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is $1.4, with high estimates of $1.71 and low estimates of $0.75.
Analysts are recommending an EPS of between $7.16 and $6.62 for the fiscal current year, implying an average EPS of $6.84. EPS for the following year is $7.28, with 22.0 analysts recommending between $9.33 and $3.42.
Revenue Estimates
13 analysts predict $1.35B in revenue for. The current quarter. It ranges from a high estimate of $1.43B to a low estimate of $1.31B. As of. The current estimate, Incyte Corp’s year-ago sales were $1.18BFor the next quarter, 13 analysts are estimating revenue of $1.19B. There is a high estimate of $1.24B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 14 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $5.06B, while the lowest revenue estimate was $4.89B, resulting in an average revenue estimate of $4.96B. In the same quarter a year ago, actual revenue was $4.24BBased on 21 analysts’ estimates, the company’s revenue will be $5.42B in the next fiscal year. The high estimate is $5.71B and the low estimate is $5.11B.
